Zymeworks Inc.

Key metrics

Financial performance

Over the last 5 fiscal years Zymeworks Inc.'s revenue grew from $38.95M to $105.97M, a compound annual growth rate of 22.2%. Net profit margin expanded from -463.5% to -76.6% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (323 filings)

Recent press releases

• Zymeworks Announces Participation in Upcoming Investor Conferences2026-05-22

  Zymeworks Announces Participation in Upcoming Investor Conferences | Zymeworks Inc.

• Zymeworks Appoints Kristin Stafford as Chief Financial Officer2026-05-22

  Zymeworks Appoints Kristin Stafford as Chief Financial Officer | Zymeworks Inc.

• Zymeworks Announces Participation in Upcoming Investor Conferences2026-05-22

  Zymeworks Announces Participation in Upcoming Investor Conferences | Zymeworks Inc.

• Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock2026-05-22

  Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock | Zymeworks Inc.

• Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results Jazz announced U.S. FDA acceptance with Priority Review of Supplemental Biologics License Application (sBLA) for zanidatamab in first-line HER2-positive unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA); PDUFA target action date of August 25, 2026 China’s NMPA has 05.07.20262026-05-22

  Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results | Zymeworks Inc.

Similar companies

The largest companies sharing Zymeworks Inc.'s SEC industry classification (pharmaceutical preparations).